Pathology, research and practice最新文献

{"title":"Clinicopathological significance of identifying glypican 3 -positive gastric cancer","authors":"Hai-fen Ma ,&nbsp;Zi-ning Li ,&nbsp;Jun-qiang Li ,&nbsp;Min Wang ,&nbsp;Wei-hua Xiao ,&nbsp;Peng Shu ,&nbsp;Xiao-hai Shi","doi":"10.1016/j.prp.2025.156089","DOIUrl":"10.1016/j.prp.2025.156089","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study was to investigate the expression of Glypican 3 (GPC3) in gastric cancer and to identify clinicopathological prognostic factors associated with GPC3-positive gastric cancer (GPC3-GC).</div></div><div><h3>Methods</h3><div>Gene expression and survival differences of GPC3 were analyzed by the TCGA-STAD database and immunohistochemical detection in the gastric adenocarcinoma tissues.</div></div><div><h3>Results</h3><div>Bioinformatic analysis revealed that the GPC3 gene was highly expressed in gastric adenocarcinoma tissues (P &lt; 0.05), and Univariate Cox regression analysis further demonstrated that the hazard ratio (HR) for GPC3 was 1.8 (95% CI: 1.3-2.5) (P &lt; 0.001). Among the 218 cases of gastric adenocarcinoma tissue samples in this study, the positive rate of GPC3 was 17.0 % (37/218), increasing to 53.6 % (15/28) in cases with elevated serum AFP. Liver metastasis is more common in GPC3-positive gastric cancer (P &lt; 0.001). GPC3-positive was more prevalent in adenocarcinomas with hepatoid or enteroblastic differentiation, depth of T3 + T4, clinical TNM stage III+IV (all P &lt; 0.05). The Kaplan-Meier results revealed significant differences between the GPC3-negative and GPC3-positive groups (P &lt; 0.001). However, no significant difference was found between GPC3-focal and diffuse tumors (P &gt; 0.05). Cox regression analyses identified GPC3-positive as a risk factor affecting postoperative prognosis in gastric adenocarcinoma (P &lt; 0.001). However, GPC3 can’t serve as a prognostic indicator independent of other indicators (P &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>GPC3 is expressed in some cases of gastric adenocarcinoma, particularly in cancers with elevated serum AFP levels, providing a potential basis for clinical monitoring and exploring new immunotherapy targets. GPC3-GC often exhibits strong invasive and metastatic capabilities and may carry a poor prognosis, especially in cases with enteroblastic differentiation and elevated serum AFP. Therefore, it is crucial to enhance awareness and differentiate GPC3-GC from common adenocarcinoma.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156089"},"PeriodicalIF":2.9,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144329632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From EGFR mutations to STAT30-driven resistance in NSCLC: Biomarkers and multi-modal treatment approach","authors":"Surya Nath Pandey ,&nbsp;Kavita Goyal ,&nbsp;Mohit Rana ,&nbsp;Soumya V. Menon ,&nbsp;Subhashree Ray ,&nbsp;Mandeep Kaur ,&nbsp;Swati Sharma ,&nbsp;Abida Khan","doi":"10.1016/j.prp.2025.156087","DOIUrl":"10.1016/j.prp.2025.156087","url":null,"abstract":"<div><div>Non–small-cell lung cancer (NSCLC) accounts for approximately 85 % of lung cancer cases and remains the leading cause of cancer mortality worldwide. However, the emergence of drug resistance and tumor immune evasion limits long-term treatment efficacy and reduces overall patient survival. We examine how activating EGFR mutations or overexpression induce STAT3 phosphorylation and regulate transcription factors such as Snail, Twist, and ZEB1. Next, we critically evaluate therapies ranging from first- to third-generation EGFR tyrosine kinase inhibitors and novel STAT3 antagonists to immune checkpoint inhibitors. Although numerous preclinical studies demonstrate synergistic activity when EGFR-TKIs are combined with STAT3 inhibitors or ICIs, clinical trial data remain sparse and preliminary. Preclinical studies of Polyphyllin I and MTI31 illustrate the reversal of epithelial-mesenchymal transition and restoration of sensitivity to EGFR-targeted agents. In contrast to previous reviews, we offer a comparative analysis of monotherapy versus combination regimens, highlight remaining knowledge gaps, and propose an integrated framework for co-targeting EGFR, STAT3, and immune checkpoints. We aim to elucidate EGFR–STAT3 signaling crosstalk in NSCLC and distinguish preclinical findings from clinical data to enhance the translational relevance of combination therapies.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156087"},"PeriodicalIF":2.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144313426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dedifferentiated liposarcoma exhibiting myxoid liposarcoma-like morphology with DDIT3 co-amplifcation and STAT6 nuclear expression","authors":"Bohui Zhang,&nbsp;Hong Li,&nbsp;Zhixing Cao,&nbsp;Huihui Cao","doi":"10.1016/j.prp.2025.156086","DOIUrl":"10.1016/j.prp.2025.156086","url":null,"abstract":"<div><div>Dedifferentiated liposarcoma (DDLPS) arises from atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS) through progression into non-lipogenic sarcomas of varying histological grades, driven by amplification of the chromosome 12q13-15 region containing <em>MDM2, CDK4, DDIT3, STAT6, GLI1, HMGA2,</em> etc. DDLPS demonstrates marked morphological heterogeneity in its dedifferentiated components. We describe two DDLPS cases featuring a prominent arborizing vascular network, myxoid stroma, and STAT6 nuclear expression—features that complicate differentiation from solitary fibrous tumors (SFT), myxoid liposarcoma (MLPS), myxofibrosarcoma (MFS), <em>GLI1</em>-altered tumors, low-grade fibromyxoid sarcoma (LGFMS), soft tissue angiofibroma (STA), etc. Immunohistochemistry (IHC) confirmed STAT6 overexpression, while fluorescence in situ hybridization (FISH) revealed co-amplification of <em>MDM2</em> and <em>DDIT3</em>. <em>STAT6</em> amplification in DDLPS leads to detectable protein expression by IHC. <em>DDIT3</em> amplification in select WDLPS/DDLPS cases correlates with such unique MLPS-like morphology. These observations imply that analogous mechanisms may involve other genes within the 12q13-15 region, underscoring the genomic and phenotypic heterogeneity of DDLPS. Tumor diagnosis requires integrating morphological assessment, immunohistochemistry, molecular testing, clinical context, and imaging findings rather than relying on isolated genetic or immunohistochemical markers. This represents the first reported instance of DDLPS with MLPS-like morphology accompanied by <em>MDM2</em> and <em>DDIT3</em> co-amplification and concurrent STAT6 nuclear expression.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156086"},"PeriodicalIF":2.9,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of the Nrf2 pathway in inhibiting ferroptosis in kidney disease and its future prospects","authors":"Jia-Yuan Huang,&nbsp;Hai-ning Yu","doi":"10.1016/j.prp.2025.156084","DOIUrl":"10.1016/j.prp.2025.156084","url":null,"abstract":"<div><div>Kidney disease (KD) has gradually become a major social and economic burden on the healthcare system. Recent studies highlight ferroptosis as a critical mechanism in the progression of these conditions. Recognized for its essential role in renal pathogenesis, ferroptosis is attracting increasing research attention and emerging as a key focus of investigation. The Nrf2 signaling pathway, known for its regulatory influence on ferroptosis, plays a central role in this context. Activation of the nuclear factor E2-related factor 2 (Nrf2) pathway and the subsequent attenuation of ferroptosis present substantial opportunities as novel therapeutic targets for managing kidney injury (KI). This article summarizes the latest mechanism of action of the Nrf2 pathway in ferroptosis, explores how the Nrf2 pathway affects ferroptosis in KD therapy, and investigates the potential therapeutic effects of natural products targeting the Nrf2 pathway. These natural products have been shown to inhibit ferroptosis through the Nrf2 pathway, providing new insights and therapeutic strategies for the clinical and individualized management of KD.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156084"},"PeriodicalIF":2.9,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144291078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integration of machine learning in biomarker discovery for esophageal squamous cell carcinoma: Applications and future directions","authors":"Wanli Yang ,&nbsp;Lili Duan ,&nbsp;Xinhui Zhao ,&nbsp;Liaoran Niu ,&nbsp;Chenyang Wang ,&nbsp;Daiming Fan ,&nbsp;Liu Hong","doi":"10.1016/j.prp.2025.156083","DOIUrl":"10.1016/j.prp.2025.156083","url":null,"abstract":"<div><h3>Purpose</h3><div>Recent advancements in sequencing technologies and bioinformatics algorithms have facilitated significant breakthroughs in both fundamental and clinical tumor research. Nevertheless, the processing and utilization of large-scale data continue to pose substantial challenges. Machine learning (ML)-based integrative analysis methods present a novel approach for navigating these complex datasets, thereby enhancing the understanding of tumors from multiple perspectives.</div></div><div><h3>Methods</h3><div>Here, we present a comprehensive overview of ML processes and methodologies that have the potential to advance research and management of esophageal squamous cell carcinoma (ESCC). Specifically, our focus is on their application in key areas such as early detection, prognosis prediction, therapeutic target identification, and drug discovery. Additionally, we examine the challenges and opportunities that ML introduces in the context of ESCC research.</div></div><div><h3>Results</h3><div>Our findings indicate that ML techniques have the capacity to enhance medical decision-making, improve patient care, and drive progress in healthcare. The prospective integration of ML in oncology poses several challenges, highlighting the need for interdisciplinary collaboration. Addressing these challenges will require coordinated efforts from medical professionals, data scientists, information technology specialists, and policymakers.</div></div><div><h3>Conclusions</h3><div>The identification of biomarkers for ESCC via ML significantly enhances the quality of medical care and supports expert diagnostic and therapeutic decision-making, thereby markedly improving diagnostic efficiency and advancing the field of intelligent healthcare.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156083"},"PeriodicalIF":2.9,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heterogeneity of tumor-associated macrophages in colorectal cancer: Origins, classification, and immunotherapeutic implications","authors":"Yuna Li ,&nbsp;Zhaohui Huang ,&nbsp;Yuan Yin","doi":"10.1016/j.prp.2025.156082","DOIUrl":"10.1016/j.prp.2025.156082","url":null,"abstract":"<div><div>Tumor microenvironment (TME) plays an important role in the occurrence, progression, and therapeutic response of malignant tumor. As the main immune cells in TME, tumor-associated macrophages (TAMs) are considered to be potential key targets for cancer diagnosis and treatment. However, the functional roles and clinical significance of TAMs in colorectal cancer (CRC) remains controversial. These controversies may stem from the dynamic changes in TME and the high heterogeneity of TAMs. In this review, we systematically explore the sources, classification, identification methods and clinical significance of TAM heterogeneity in CRC. We also summarize current therapeutic approaches targeting TAMs and their limitations. In addition, differences in the function of TAMs in different stages and subtypes of CRC were analyzed, highlighting their interactions with other immune cells and signaling pathways. It suggests that developing novel therapeutic strategies based on TAM heterogeneity holds promise for advancing precision monitoring and treatment of CRC, and promote the further development of tumor immunotherapy.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156082"},"PeriodicalIF":2.9,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144291205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-altitude physiology: Understanding molecular, pharmacological and clinical insights","authors":"B. M. Redwan Matin Zidan ,&nbsp;Mehrukh Zehravi ,&nbsp;Shaik Kareemulla ,&nbsp;Kallam Sudha Divya Madhuri ,&nbsp;Jeetendra Kumar Gupta ,&nbsp;Voleti Vijaya Kumar ,&nbsp;Jishan Khan ,&nbsp;Ali G. Alkhathami ,&nbsp;Hamid Osman ,&nbsp;Mayeen Uddin Khandaker ,&nbsp;Talha Bin Emran","doi":"10.1016/j.prp.2025.156080","DOIUrl":"10.1016/j.prp.2025.156080","url":null,"abstract":"<div><div>Acute mountain sickness (AMS), high-altitude pulmonary edema (HAPE), and high-altitude cerebral edema (HACE) are three common forms of altitude sickness. These conditions can be life-threatening, with symptoms like fatigue, dizziness, and headaches. Ascending to high elevations increases the likelihood of developing these conditions, with some individuals adapting quickly while others need to descend. Early acclimatization is beneficial for avoiding AMS and HACE, but it takes weeks to months to improve job performance and performance at high altitudes. HAPE is a leading cause of mortality from altitude sickness, characterized by foamy mucus, coughing, and difficulty breathing. Treatment is most effective when it is administered quickly, with mild cases resolving with additional time spent at altitude. Oxygen therapy and chemicals such as acetazolamide, spironolactone, and dexamethasone are used to restore fluid balance and prevent complications. Genes and environmental factors influence genetic reactions to low oxygen levels at high altitudes. This review explores pharmacological interventions currently used or under investigation, such as acetazolamide, dexamethasone, and novel HIF stabilizers. By integrating molecular insights with pharmacological data, we aim to provide a comprehensive understanding of altitude-related illnesses. Studying altitude sickness is highly relevant not only for climbers and high-altitude workers but also for broader medical contexts like hypoxia-related diseases. This manuscript aims to bridge the gap between basic science and clinical practice, facilitating improved strategies for management and prevention of high-altitude disorders.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156080"},"PeriodicalIF":2.9,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144270405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autophagy in disease management: Exploring the potential of natural products as targeted therapies","authors":"Laila A. Eissa ,&nbsp;Amani M. Marawan ,&nbsp;Mohamed E. Marawan ,&nbsp;Shimaa A. Abass","doi":"10.1016/j.prp.2025.156077","DOIUrl":"10.1016/j.prp.2025.156077","url":null,"abstract":"<div><div>Autophagy is a vital cellular process that degrades and recycles intracellular components <em>via</em> lysosomes, playing a key role in maintaining cellular homeostasis. Alteration of this mechanism has been implicated in the occurrence and progression of numerous diseases, including cancer, neurodegenerative disorders, cardiovascular conditions, and microbial and viral infections. Recent studies have identified several mutations affecting autophagy-related genes and elucidated how defective degradation of specific substrates contributes to disease mechanisms. Natural products are gaining attention for their ability to modulate autophagy through several molecular targets. Herin, we highlight the complicated role of autophagy in disease pathogenesis. We also illustrate how natural products may offer therapeutic value by targeting autophagy in different pathological contexts.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156077"},"PeriodicalIF":2.9,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144270406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors and therapeutic significance of HER2 overexpression in urothelial carcinoma","authors":"Chunjin Ke ,&nbsp;Jie Wan ,&nbsp;Guoping Wang ,&nbsp;Zhiquan Hu ,&nbsp;Chunguang Yang","doi":"10.1016/j.prp.2025.156079","DOIUrl":"10.1016/j.prp.2025.156079","url":null,"abstract":"<div><h3>Objective</h3><div>We analyzed the expression of HER2 in urothelial carcinoma (UC) and the risk factors for overexpression, and then further explored the guiding significance of HER2 in the treatment of locally progressive and advanced UC.People's Republic of China</div></div><div><h3>Methods</h3><div>Immunohistochemistry (IHC) was used to detect HER2, luminal markers (CK20, GATA3), and basal markers (CK5/6, CD44). HER2 overexpression was defined as IHC 2 + or IHC 3 + . Binary logistic regression was used to analyze the risk factors for HER2 overexpression. The therapeutic significance of HER2 was preliminarily discussed through case analysis.</div></div><div><h3>Results</h3><div>A total of 119 patients with UC were included in this study, including 99 males and 20 females, with an average age of 66.2 ± 9.6 years. UC were derived from the bladder [n = 97 (81.5 %)], renal pelvis [n = 15 (12.6 %)], ureter [n = 6 (5.0 %)] and prostate [n = 1 (0.8 %)], respectively. UC were classified according to molecular typing into luminal 76 (63.9 %) cases and basal 29 (24.4 %) cases. HER2 expression rates of IHC 0, 1 + , 2 + , and 3 + in UC were 39.5 %, 23.5 %, 31.9 %, and 5 %, respectively. HER2 overexpression was as high as 52.6 % in luminal patients, but only 3.4 % in basal patients (53.2 % vs 3.4 %, P &lt; 0.001). HER2 overexpression was strongly correlated with lower urinary tract, invasive, high-grade, multiple tumors and luminal (P &lt; 0.05), while no significant correlation was seen with patients' gender (P = 0.311), age (P = 0.722), lymph node metastasis (P = 0.282) and ki67 index (P = 0.964). Multiple tumors (OR=5.346, 95 %CI: 1.921–14.877, P = 0.001) and luminal (OR=28.827, 95 %CI: 2.768–300.225, P = 0.005) were independent risk factors for HER2 overexpression. cT2N0M0 patient with HER2 (2 +) showed significant tumor shrinkage after preoperative neoadjuvant therapy with RC48-ADC.</div></div><div><h3>Conclusions</h3><div>HER2 testing can be routinely done in patients with locally advanced or metastatic UC, multiple tumors and luminal. Neoadjuvant therapy (HER2-ADC) for locally advanced UC was found to significantly shrink tumors, providing a theoretical basis for organ preservation and functional protection in genitourinary tumor surgery. HER2-ADC may be effective and safe in the treatment of locally progressive or advanced UC.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156079"},"PeriodicalIF":2.9,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian high-grade follicular thyroid carcinoma with teratoma and NRAS mutation in an adolescent female: A case report","authors":"Yuqing Wei ,&nbsp;Yan Cao ,&nbsp;Wen Liu ,&nbsp;Zongjing Zhang ,&nbsp;Peifeng Li","doi":"10.1016/j.prp.2025.156076","DOIUrl":"10.1016/j.prp.2025.156076","url":null,"abstract":"<div><div>Ovarian follicular thyroid cancer (OFTC) is a rare malignant struma ovarii that usually occurs in women aged between 30 and 50 years. The molecular pathogenesis and prognostic factors of OFTC remain poorly understood. Here, we present a case of a large cystic and solid mass in the left ovary of a 15-year-old female patient, who underwent single-port laparoscopic left adnexectomy. In addition to mature teratoma containing normal thyroid tissue, the tumor of thyroid cell origin had a nest-like or lamellar structure with intravascular thrombus, coagulation necrosis, and high mitotic image count, and lacked the nuclear features of papillary thyroid carcinoma. Immunohistochemical markers were positive for PAX-8, TTF-1 and TG. The final diagnosis was high-grade OFTC with teratoma. <em>NRAS</em> (Q61R) mutations were detected by whole exome sequencing and fluorescence quantitative PCR in OFTC samples, indicating that the pathogenesis of the tumor resembled that of follicular carcinoma of the thyroid. The occurrence of OFTC in adolescent females is very rare. High-grade OFTC is classified based on primary thyroid cancer, and its assessment in ovarian tumors has not been reported. Further research is required to elucidate its molecular mechanisms and prognostic factors through the accumulation of more cases.</div></div>","PeriodicalId":19916,"journal":{"name":"Pathology, research and practice","volume":"272 ","pages":"Article 156076"},"PeriodicalIF":2.9,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144241285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}